Kiadis collaborates with premier Dutch institutions to apply
K-NK-cell technology for the development of a novel COVID-19
therapy
- Initiates new COVID-19 research and development program
(K-NK-ID101)
- Expands the application of Kiadis’ K-NK technology into
infectious diseases
- Announces collaboration with five premier Dutch institutions:
Viroclinics-DDL; Harbour BioMed Netherlands; Sanquin
Bloedvoorziening; Erasmus Medical Center; and the Utrecht
University, each contributing a unique strength in virology and
COVID-19 research and know how
- Submitted grant application with US government
Amsterdam, The Netherlands, August 17,
2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company developing innovative cell-based
medicines for life-threatening diseases, announces a new research
program, K-NK-ID101, that will focus on the development of K-NK
cells as a treatment for COVID-19. This new program marks the start
of broader application of Kiadis’ K-NK technology platform as a
potential treatment, not only for cancer, but also for infectious
diseases.
In support of the K-NK-ID101 program, Kiadis has
started collaborating with five premier Dutch institutions to study
different anti-viral mechanisms of Kiadis’ K-NK cell therapy
platform against SARS-CoV-2, the virus that caused the COVID-19
pandemic. The collaboration will study NK-cell biology in COVID-19
patients, the elimination of SARS-CoV-2 virus and virally infected
cells by K-NK cells, and synergies between monoclonal antibodies,
vaccines and K-NK cells.
Natural killer (NK) cells are the human immune
system’s first line of defence against tumor cells and infectious
disease. Activity of K-NK cells has been demonstrated against
cytomegalovirus (CMV) and BK virus in the K-NK002 clinical trials,
and against CNS and pulmonary fungal and bacterial agents in the
K-NK003 clinical trials.
COVID-19 breaks down NK cell immunity, and
severe COVID-19 patients lack functional NK cells. K-NK-ID101 cells
potentially have enhanced anti-viral activity, while avoiding
exacerbating needless inflammation, and therefore may be uniquely
suited to repair this lack of functional NK cells. Since K-NK-ID101
cells can be manufactured at large scale and frozen down, they can
be immediately and globally made available to patients. Also, the
broad anti-viral activity of K-NK cells could potentially serve as
a universal countermeasure to fight future viral pandemics; Kiadis
will learn more about the potential of the platform through
research conducted through these collaborations.
Robert Friesen, PhD, chief scientific officer of
Kiadis, commented, “Our unique K-NK-cell technology platform is
broadly applicable across a range of therapeutic areas. While our
initial focus has been targeted towards blood cancers, we are now
expanding our research into infectious diseases and have
established relationships with anti-viral and COVID-19 academic and
drug development experts, to develop our K-NK-cell therapeutics for
the treatment of COVID-19. Significant data suggests that our
K-NK-ID101 cell therapy could offer a unique and meaningful
treatment of COVID-19. We look forward to working with this
esteemed group to efficiently contribute to the fight against this
pandemic.”
Arthur Lahr, chief executive officer of Kiadis,
added, “We believe that medicines based on K-NK cells could be an
important part of the armamentarium needed to fight this global
pandemic, and offer a potential universal pandemic preparedness
platform. To support the K-NK-ID101 program, we have applied for
grants with the US government put in place in this global fight
against COVID-19. This program demonstrates the breadth of
application of our K-NK platform and marks the start of broader
application of K-NK cells as a potential treatment, not only for
cancer, but also for infectious diseases.”
Kiadis’ collaborators include leaders in
SARS-CoV-2 research from the Department of Viroscience of Erasmus
Medical Center Rotterdam and the Division of Infectious Diseases of
the Veterinary Faculty of Utrecht University. These two academic
groups were the first to report a monoclonal antibody that prevents
the SARS-CoV-2 virus from infecting cultured cells (Nature Com. 11
2215, 2020). Harbour BioMed Netherlands will bring the potent
SARS-CoV-2 antibodies resulting from that research to Kiadis’
program. Complementing the program is Viroclinics Xplore, which
owns proprietary viral disease models, assays and animal models for
SARS-CoV-2. Viroclinics-DDL is a renowned world class viral
contract research organization, and has contributed significantly
to viral research for previous pandemics, including SARS1 and
pandemic flu. Sanquin will perform characterization of NK-cell
presence and function in recovered COVID-19 patients, using its
unique pool of donor material across the Dutch population.
About Kiadis’ K-NK-Cell
Therapies Kiadis’ K-NK-cell therapy research programs in
immuno-oncology consist of off-the-shelf and haploidentical donor
cell therapy products for the treatment of liquid and solid
tumors as adjunctive and stand-alone therapies. Kiadis is also
researching the use of its K-NK cell therapy platform for the
treatment of infectious diseases, with the first potential
application being the treatment of COVID-19.
The Company’s PM21 particle technology enables
improved ex vivo expansion and activation of anti-cancer cytotoxic
K-NK-cells supporting multiple high-dose infusions. Kiadis’
proprietary off-the-shelf K-NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis is clinically developing K-NK003 for the
treatment of relapse/refractory acute myeloid leukemia. The Company
is also developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About NK-cells and K-NK-cells in
COVID-19The scientific rationale for studying the
infusion of natural killer (NK) cells to control COVID-19 disease
is supported by literature. The vast majority of COVID-19 patients
have lymphocytopenia, or a shortage of lymphocytes – a type of
white blood cell that helps protect the body from infection. NK
cells are lymphocytes and COVID-19 disease severity is correlated
with a reduction in the number of NK cells, exhaustion of NK cells
and the lack of certain mature, potent NK-cell phenotypes. The
power of NK cells to fight various other viral infections, such as
CMV, BKV, HBV and HCV, has been well described, with a durable
change in the NK-cell profile towards those more mature and potent
phenotypes in recovered patients.
Kiaidis research is aimed at studying the
properties of Kiadis K-NK cells and their suitablilty to fight
SARS-CoV-2 and to be developed as pre-exposure prophylaxis and
post-exposure pre-emptive therapy in high risk patients and
healthcare workers. K-NK cells enhance multiple aspects of
antiviral immunity. In immunocompromised transplant patients, K-NK
cells have shown significant reduction of potentially lethal CMV
reactivation and BKV infection. K-NK cells work synergistically
with antibodies, immunoglobulins and vaccines.
K-NK cells are being studied regarding their
anti-viral properties, safety profile and manufacturing scalability
to potentially be widely deployed as an off-the-shelf global
countermeasure against COVID-19 and future pandemic threats.
Kiadis contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring LifeSciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V. (Euronext Amsterdam
en Brussel: KDS) is een Nederlands beursgenoteerd
biotechbedrijf dat nieuwe geneesmiddelen ontwikkelt tegen ernstige
ziekten. Het maakt daarbij gebruik van Natural Killer-cellen
(NK-cellen), grote witte bloedlichamen die de eerste
verdedigingslinie in het menselijk afweersysteem vormen tegen
kankercellen en infecties. Kiadis is met haar unieke
Kiadis-NK-cellen (K-NK-cellen) een nieuw onderzoeksprogramma
gestart genaamd K-NK-ID01, voor de behandeling van COVID-19, de
ziekte die wordt veroorzaakt door het SARS-CoV-2 virus. Kiadis
breidt hiermee de toepassing van K-NK-cellen uit naar behandeling
van kanker en infectieziekten.
Kiadis gaat samen met Erasmus MC, Universiteit
Utrecht, Sanquin Bloedvoorziening en de Nederlandse bedrijven
Viroclinics en Harbour BioMed Netherlands, onderzoek doen naar de
werking van de Kiadis’ K-NK-cellen tegen het corona virus dat
COVID-19 veroorzaakt. Daarbij zullen de partijen onder andere
onderzoeken hoe de K-NK-cellen kunnen worden gecombineerd met al
eerder door Erasmus MC, Harbour BioMed en Universiteit
Utrecht-ontdekte antilichamen tegen het coronavirus.
Patiënten met ernstige COVID-19 hebben een
gebrek aan goed werkende NK-cellen. In eerdere Kiadis
onderzoeksprogramma’s is krachtige werking van Kiadis’ K-NK-cellen
aangetoond tegen diverse virale, schimmel- en bacteriële infecties
in het bloed, de longen en het centrale zenuwstelsel van ernstig
zieke patiënten met kanker die zelf geen goed functionerende NK
cellen meer hebben. Kiadis’ K-NK-ID101-cellen kunnen mogelijk ook
het gebrek aan goed werkende NK-cellen bij COVID-19 patiënten
herstellen.
K-NK-ID101 cellen kunnen in de toekomst op grote
schaal worden geproduceerd en onmiddellijk voor patiënten
beschikbaar worden gemaakt. De brede werking van NK-cellen tegen
diverse virussen maakt K-NK-ID101-cellen daarmee mogelijk een
universeel middel in de strijd tegen wereldwijde pandemieën.
Robert Friesen, Ph.D, Chief Scientific Officer van
Kiadis, zegt:
“Ons unieke K-NK-cel-technologieplatform is
breed toepasbaar voor meerdere ziekten. We hadden al diverse
onderzoeks programma’s voor de behandeling van kanker, en breiden
onze activiteiten nu uit naar behandeling van infectieziekten. Onze
K-NK-ID101-celtherapie kan mogelijk tot een unieke behandeling van
COVID-19 leiden. We kijken er naar uit om samen met dit sterke
netwerk van gerenommeerde Nederlandse onderzoeksgroepen een
effectieve behandeling te ontwikkelen in de strijd tegen het
coronavirus dat de COVID-19 pandemie veroorzaakt."
Arthur Lahr, chief executive officer van Kiadis, vult
aan: “K-NK-cellen kunnen in de toekomst op grote schaal
geproduceerd worden en onmiddellijk beschikbaar komen bij
behandeling van diverse virale infecties. Geneesmiddelen op basis
van K-NK-cellen kunnen daarmee mogelijk een belangrijk wapen vormen
tegen deze en toekomstige pandemieën. We hebben voor dit
K-NK-ID101-programma subsidie aangevraagd bij de Amerikaanse
overheid. Dit programma toont het brede potentieel van ons
K-NK-platform, niet alleen als mogelijk medicijn tegen kanker, maar
ook voor behandeling van infectieziekten.”
Universitaire specialisten in SARS-CoV-2-onderzoek van de
afdeling Viroscience van het Erasmus Medisch Centrum in Rotterdam
en de afdeling Infectieziekten van de Veterinaire Faculteit van
Universiteit Utrecht nemen deel aan de samenwerking. Deze
academische groepen ontdekten als eerste monoklonale antilichamen
die infectie met het SARS-CoV-2-virus tegengaan (Nature Com.
(2020)11: 2215). Harbour BioMed Netherlands zal
deze SARS-CoV-2-antilichamen in de samenwerking inbrengen.
Viroclinics is een gerenommeerde contractonderzoeksorganisatie en
heeft baanbrekend onderzoek gedaan bij eerdere pandemieën,
waaronder SARS en pandemische griep. Viroclinics is eigenaar van
gepatenteerde virale ziektemodellen, testen en diermodellen voor
SARS-CoV-2. Sanquin Bloedvoorziening zal de aanwezigheid en functie
van NK-cellen bij COVID-19 patiënten in kaart brengen, gebruik
makend van donormateriaal van herstelde COVID-19 patiënten.
Dit persbericht vormt een vertaling van
het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
bepalend.
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative cell-based medicines for
patients with life-threatening diseases. With headquarters in
Amsterdam, the Netherlands, and activities across the United
States, Kiadis is reimagining medicine by leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person’s officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.